Vandenplas, Yannick http://orcid.org/0000-0002-6028-8486
Simoens, Steven http://orcid.org/0000-0002-9512-2005
Turk, Florian
Vulto, Arnold G. http://orcid.org/0000-0002-8439-2800
Huys, Isabelle http://orcid.org/0000-0002-4738-8298
Funding for this research was provided by:
Institut National d'assurance Maladie-Invalidité
Article History
Accepted: 20 July 2022
First Online: 16 August 2022
Declarations
:
: This research project and manuscript are supported and funded by KU Leuven and the Belgian National Institute for Health and Disability Insurance.
: SS, IH, and AGV have founded the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL). SS was involved in a stakeholder roundtable on biologics and biosimilars sponsored by Amgen, Pfizer, and MSD; he has participated in advisory board meetings for Pfizer, Sandoz, and Amgen; he has contributed to studies on biologics and biosimilars for Hospira (together with AGV and IH), Celltrion, Mundipharma, and Pfizer, and he has had speaking engagements for Amgen, Celltrion, and Sandoz. AGV is involved in consulting, advisory work, and speaking engagements for a number of companies, AbbVie, Accord, Amgen, Biogen, Effik Benelux, Pfizer/Hospira, Fresenius Kabi, Mundipharma, Medicines for Europe, Roche, and Sandoz. FT acted as an advisor to and consultant of several pharmaceutical organizations and has represented pharmaceutical organizations in professional associations. All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: Not applicable.
: Not applicable.
: Not applicable.
: All data and material are available in the article and the supplementary material.
: Not applicable.
: IH, FT, AGV, SS, and YV developed the idea for and were involved in the design of the study. YV was involved in the data collection and drafted the initial version of the manuscript. IH, FT, AGV, and SS critically reviewed the manuscript. All authors read and approved the final manuscript.